Emory University School of Medicine, Atlanta GA.
J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143.
Monoclonal antibodies (elotuzumab and daratumumab) are the newest class of drugs that have proven to be efficacious antimyeloma agents. Although daratumumab, a CD38 monoclonal antibody, has established its efficacy as a single agent and in combination with immunomodulatory agents and proteasome inhibitors, elotuzumab (signaling lymphocytic activation molecule F7 monoclonal antibody) has proven activity in combination with lenalidomide and dexamethasone. Infusion-related reactions (respiratory and nonrespiratory) seem to be a common theme of adverse events with monoclonal antibodies, although the relative incidence differs across these two agents. Identifying the appropriate pre- and postinfusion medication strategies can help lower the rates of infusion-related reactions and facilitate reduction in infusion times. In this article, we review the incidence of the infusion-related reactions with elotuzumab and daratumumab and their clinical activity in myeloma, review our institutional experience of management of infusion-related reactions, and provide some practical mitigation strategies to reduce their incidence.
单克隆抗体（依鲁替尼和达雷妥尤单抗）是最新一类被证明对骨髓瘤有效的药物。虽然达雷妥尤单抗（一种 CD38 单克隆抗体）已被证实作为单一药物以及与免疫调节剂和蛋白酶体抑制剂联合使用具有疗效，但依鲁替尼（信号淋巴细胞激活分子 F7 单克隆抗体）已被证明与来那度胺和地塞米松联合使用具有活性。输注相关反应（呼吸和非呼吸）似乎是单克隆抗体不良事件的一个常见主题，尽管这两种药物的相对发生率不同。确定适当的输注前和输注后药物策略有助于降低输注相关反应的发生率，并有助于缩短输注时间。本文综述了依鲁替尼和达雷妥尤单抗的输注相关反应发生率及其在骨髓瘤中的临床活性，回顾了我们机构在输注相关反应管理方面的经验，并提供了一些实用的缓解策略，以降低其发生率。
